33. Lumoxiti

CG image of AstraZeneca's HQ
(AstraZeneca)

Active ingredient: moxetumomab pasudotox-tdfk
Disease: hairy cell leukemia
Peak sales estimate: $500 million
Approved: Sept. 13
Company: AstraZeneca

The scoop: After breaking into the blood cancer market in 2017 with Calquence, approved in mantle cell lymphoma, AstraZeneca followed up this year with its new treatment for hairy cell leukemia in patients who have undergone at least two prior therapies. While most patients respond to purine analogs including Janssen’s Leustatin (cladribine) and Pfizer’s Nipent (pentostatin), about 30% to 40% will relapse within a decade after their first treatment, a population Lumoxiti can serve. Oncology in general represents a bright spot at the struggling company thanks to immuno-oncology drug Imfinzi, which launched in 2018 as a treatment for stage 3 lung cancer that can't be surgically removed, as well as Tagrisso, a targeted lung cancer treatment. On the other hand, AstraZeneca’s hope for approval of Imfinzi as a first-line treatment for lung cancer was dashed when it failed to hit endpoints in the closely watched Mystic trial, either on its own or in combination with CTLA4 candidate tremelimumab. — Eric Palmer 

33. Lumoxiti
Read more on

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.